Q32 Bio Inc.

Clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases.

[Q32 Bio Inc. @Q32Bio]

Clinical trials are essential to our work to advance potential new treatment options for #alopeciaareata. On #ClinicalTrialsDay, we extend our gratitude to our clinical trials team and to all who support or participate in clinical research. #CTD2026

[Q32 Bio Inc. @Q32Bio]

Today we reported first quarter 2026 financial results and provided a corporate update. Learn more: https://t.co/nCHTHl1cjy $QTTB

[Q32 Bio Inc. @Q32Bio]

We look forward to participating in the 25th Annual Needham Virtual Healthcare Conference next week. Tune in to our fireside chat on Wednesday, April 15th at 12:45 p.m. ET. Find webcast details here: https://t.co/2btiqEL6ih

[Q32 Bio Inc. @Q32Bio]

Our CEO, Jodie Morrison, spoke with @BiotechTV about the ongoing Part B portion of our SIGNAL-AA clinical trial evaluating bempikibart in severe or very severe #alopeciaareata. Thanks to @bradloncar!
Learn more about bempikibart and our ongoing trial: https://t.co/eX5NDaOgvX

[BiotechTV @BiotechTV]

𝐒𝐭𝐚𝐭𝐞 𝐨𝐟 𝐏𝐨𝐬𝐬𝐢𝐛𝐥𝐞: @Q32Bio has a key phase 2 readout for its IL-7Rα in alopecia scheduled for this summer - CEO Jodie Morrison explains the science and previews it. $QTTB

Full video: https://t.co/qnypGi6BTy

[Q32 Bio Inc. @Q32Bio]

Today we reported fourth quarter 2025 financial results and provided a corporate update. Learn more: https://t.co/9SkxzrIflF $QTTB

[Q32 Bio Inc. @Q32Bio]

We look forward to participating in the @Oppenheimer 36th Annual Healthcare Life Sciences Conference next week. Tune in to our fireside chat on Wednesday, February 25th at 2:00 p.m. ET. More details here: https://t.co/WRLVLlrSmK

[Q32 Bio Inc. @Q32Bio]

Maria Marzilli has been appointed Chief Business Officer of Q32 Bio! Having been with the Company since 2019, Maria will continue to be instrumental in guiding BD as we work to advance therapies for #alopeciaareata and other #autoimmunediseases.

[Q32 Bio Inc. @Q32Bio]

Today we reported third quarter 2025 financial results and provided a corporate update. Learn more: https://t.co/iBggsP2BPW $QTTB

[Q32 Bio Inc. @Q32Bio]

We are excited to announce that we have completed enrollment and exceeded our enrollment target in Part B of our SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe #alopeciaareata (AA).

Learn more: https://t.co/bkpFU2LOKP

[Q32 Bio Inc. @Q32Bio]

We look forward to participating in a fireside chat at the 2025 @WellsFargo Healthcare Conference next week in Boston. Find webcast details here: https://t.co/BLE1aapXi1

#biotech #alopeciaareata #autoimmunediseases

[Q32 Bio Inc. @Q32Bio]

Today we reported second quarter 2025 financial results and provided a corporate update. Learn more: https://t.co/ugsidlNsbM $QTTB

[Q32 Bio Inc. @Q32Bio]

July is #InternationalWomenWithAlopeciaMonth, a time to raise awareness for #alopeciaareata (AA) and its impact on women.

Our lead candidate, bempikibart, is currently being evaluated in our SIGNAL-AA Phase 2a clinical trial for AA. Learn more: https://t.co/8bz3S6hPGp

[Q32 Bio Inc. @Q32Bio]

We enjoyed connecting with the #alopeciaareata community at the @NAAF_org 40th Annual Conference. Thanks to #NAAF for an insightful event, and to everyone who stopped by our booth to learn more about our SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata.

[Q32 Bio Inc. @Q32Bio]

We’re at the @NAAF_org 40th Annual Conference in Chicago! Attending #NAAF40Conf? Visit our booth to grab a sweet treat and learn more about our ongoing SIGNAL-AA Phase 2a clinical trial of bempikibart, a fully human anti-IL-7Rα antibody, for #alopeciaareata.

[Q32 Bio Inc. @Q32Bio]

We’re excited to attend the upcoming @NAAF_org 40th Annual Conference, the world’s largest gathering of individuals with #alopeciaareata. If you’re attending, stop by our booth to chat with our team and pick up a company gift bag!

#NAAF40Conf

[Q32 Bio Inc. @Q32Bio]

Today we reported first quarter 2025 financial results and provided a corporate update. Learn more: https://t.co/JJB0QR8YGD $QTTB

[Q32 Bio Inc. @Q32Bio]

We are pleased to announce that the U.S. FDA has granted Fast Track designation to bempikibart, a fully human anti-IL-7Rα antibody currently being evaluated in a Phase 2 program, for the treatment of #alopeciaareata. Learn more: https://t.co/MX5W85KMyD

[Q32 Bio Inc. @Q32Bio]

We are excited to announce that we have dosed the first patients in both the Part A open-label extension (OLE) and Part B of our SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with #alopeciaareata. Learn more: https://t.co/19FTue5wa8

[Q32 Bio Inc. @Q32Bio]

Today we presented additional results from Part A of our SIGNAL-AA Phase 2a clinical trial of bempikibart demonstrating encouraging activity in patients with #alopeciaareata (AA) at the 2025 @AADskin Meeting in Orlando. Learn more: https://t.co/KYOIPezDLb #AAD2025

[Q32 Bio Inc. @Q32Bio]

Today @Q32Bio reported Q3 '24 results and provided our corporate update. To view our most recent press release and learn more, please visit https://t.co/ptuFw4q6G5. #Q32Bio #QTTB